A significantly high expression of human epidermal growth factor receptor 2 (HER2) in GBM (139), renal cell (140) and breast cancer (141) makes it an ideal candidate to develop immunotherapy using HER2-CAR-modified NK cells. This evidence concerns the gene ERBB2 and glioblastoma.